StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about ZNTL. Only you ever see it.
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $4.32 | $4.09 | -5.32% | 2.6M |
| 05-15 | $4.00 | $4.05 | +1.25% | 0.9M |
| 05-18 | $4.00 | $3.63 | -9.25% | 3.2M |
| 05-19 | $3.59 | $3.54 | -1.39% | 0.8M |
| 05-20 | $3.54 | $3.71 | +4.80% | 1.4M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregate of 15 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows ZNTL's percentile within the scored universe — observational ranking, not a recommendation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-04 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | Not available | $-152.81M | $-115.42M | $-81.68M | $-45.62M |
Net Income | Not available | $-137.06M | $-101.84M | $-75.15M | $-48.28M |
EPS (Diluted) | $-0.47 | $-1.91 | $-1.42 | $-1.05 | $-0.67 |
Total Assets | Not available | $288.97M | $327.25M | $351.71M | $384.02M |
Total Liabilities | Not available | $72.76M | $74.38M | $77.21M | $88.64M |
Cash & Equivalents | Not available | $35.99M | $39.07M | $37.60M | $41.93M |
Free Cash Flow OCF − CapEx | Not available | $-125.25M | $-94.31M | $-67.34M | $-32.64M |
Shares Outstanding | Not available | 69.09M | 72.25M | 72.14M | 71.95M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.